Bi-Jun Wang1, Jun-Yi Chen2, Yu Guan2, Da-Chao Liu1, Zi-Chuan Cao1, Jin Kong1, Zheng-Sheng Wu3, Wen-Yong Wu1. 1. Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. 2. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, PR China. 3. Department of Pathology, Anhui Medical University, Hefei, Anhui, China.
Abstract
BACKGROUND: Both meta-analyses and systematic reviews were used to assess the relationship between purinergic receptor P2X ligand-gated ion channel 7 (P2RX7) rs3751143 polymorphism and the risk of cancer. MATERIALS AND METHODS: The data used in this research were collected from Google Scholar, Web of Science, CNKI, and Wan Fang Data databases. The final retrieval ended on 22 February 2019. The strength of correlation was assessed using odds ratios and 95% confidence intervals. Based on the heterogeneity test results, fixed-effect (Mantel-Haenszel) or random-effects (DerSimonian-Laird) models were selected to summarise the collective effects. RESULTS: Eight separate studies containing 1462 cancer cases and 3037 controls were enrolled. Overall, there was no significant association between P2RX7 rs3751143 polymorphism and the risk of cancer in the allelic, homozygous, heterozygous, dominant, or recessive models. CONCLUSIONS: Our meta-analysis indicates that there is no significant association between P2RX7 rs3751143 polymorphism and the risk of cancer in the allelic, homozygous, heterozygous, dominant, and recessive models.
BACKGROUND: Both meta-analyses and systematic reviews were used to assess the relationship between purinergic receptor P2X ligand-gated ion channel 7 (P2RX7) rs3751143 polymorphism and the risk of cancer. MATERIALS AND METHODS: The data used in this research were collected from Google Scholar, Web of Science, CNKI, and Wan Fang Data databases. The final retrieval ended on 22 February 2019. The strength of correlation was assessed using odds ratios and 95% confidence intervals. Based on the heterogeneity test results, fixed-effect (Mantel-Haenszel) or random-effects (DerSimonian-Laird) models were selected to summarise the collective effects. RESULTS: Eight separate studies containing 1462 cancer cases and 3037 controls were enrolled. Overall, there was no significant association between P2RX7 rs3751143 polymorphism and the risk of cancer in the allelic, homozygous, heterozygous, dominant, or recessive models. CONCLUSIONS: Our meta-analysis indicates that there is no significant association between P2RX7 rs3751143 polymorphism and the risk of cancer in the allelic, homozygous, heterozygous, dominant, and recessive models.
Authors: Anne N Shemon; Ronald Sluyter; Suran L Fernando; Alison L Clarke; Lan-Phuong Dao-Ung; Kristen K Skarratt; Bernadette M Saunders; Khai See Tan; Ben J Gu; Stephen J Fuller; Warwick J Britton; Steven Petrou; James S Wiley Journal: J Biol Chem Date: 2005-11-01 Impact factor: 5.157
Authors: Ulf Thunberg; Gerard Tobin; Anna Johnson; Ola Söderberg; Leonid Padyukov; Magnus Hultdin; Lars Klareskog; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: Nichole K Escalante; Kevin M Jude; Junel Sotolongo Bellon; Juan L Mendoza; Leon Su; Tim M Horton; Naotaka Tsutsumi; Steven J Berardinelli; Robert S Haltiwanger; Jacob Piehler; Edgar G Engleman; K Christopher Garcia Journal: Nature Date: 2019-02-27 Impact factor: 49.962
Authors: Elena Piskounova; Michalis Agathocleous; Malea M Murphy; Zeping Hu; Sara E Huddlestun; Zhiyu Zhao; A Marilyn Leitch; Timothy M Johnson; Ralph J DeBerardinis; Sean J Morrison Journal: Nature Date: 2015-10-14 Impact factor: 49.962
Authors: Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari Journal: Purinergic Signal Date: 2021-08-04 Impact factor: 3.765